An investigation on behalf of investors in ArQule, Inc. (NASDAQ:ARQL) shares over potential wrongdoing at ArQule, Inc. was announced and NASDAQ:ARQL stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 09/01/2017 -- An investigation was announced for investors in NASDAQ:ARQL shares concerning potential breaches of fiduciary duties by certain officers and directors at ArQule.
Investors who purchased shares of ArQule, Inc. (NASDAQ:ARQL) and have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain ArQule directors breached their fiduciary duties.
Burlington, MA based ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. ArQule, Inc. reported that its annual Total Revenue declined from $11.24 million in 2015 to $4.71 million in 2016 and that its Net Loss increased from $13.77 million in 2015 to $22.72 million in 2016.
Shares of ArQule, Inc. (NASDAQ:ARQL) declined in April 2017 to as low as $0.94 per share.
On August 31, 2017, NASDAQ:ARQL shares closed at $1.09 per share.
Those who purchased shares of ArQule, Inc. have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels